Clinical Trials for Chronic Myelomonocytic Leukemia

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

NCT ID: NCT03418038

This clinical trial is studying the combined effect of ascorbic acid (a form of vitamin C) and chemotherapy on patients with certain types of lymphoma that have either come back after treatment or ...

Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

NCT ID: NCT07071155

This clinical trial is studying a new treatment approach for people with certain rare blood cancers called myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) or chronic neutrophilic leukemia (...

Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

NCT ID: NCT06630221

This clinical trial is investigating a drug called eltrombopag as a possible new treatment for patients with low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) who ...

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

NCT ID: NCT04093570

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

NCT ID: NCT07046078

This clinical trial is studying a new treatment approach for adults aged 60 and older who have been recently diagnosed with a high-risk form of acute myeloid leukemia (AML) or other similar serious...

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

NCT ID: NCT06815003

This clinical trial is studying a new way to help prevent graft versus host disease (GVHD) in patients who are receiving a stem cell transplant from a donor. GVHD can happen when the donor cells at...

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

NCT ID: NCT03326921

This clinical trial is testing a new type of immunotherapy called HA-1 T cell therapy to treat patients with certain types of acute leukemia that have come back, are not responding to treatment, or...

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

NCT ID: NCT06523556

This clinical trial is looking at a new treatment option for patients with certain serious blood cancers, including advanced phase myeloproliferative neoplasms (MPN), which are conditions where the...

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

NCT ID: NCT03128034

This clinical trial is looking at a new treatment called 211^astatine-BC8-B10 for patients with certain types of blood cancers, including high-risk acute myeloid leukemia (AML), acute lymphoblastic...

Oral-ATO for TP53-mutated Myeloid Malignancies

NCT ID: NCT06778187

This clinical trial is studying the effectiveness of a medication called oral arsenic trioxide (Arsenol ®) combined with vitamin C and other low-intensity therapies for patients with certain types ...

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

NCT ID: NCT05600894

This clinical trial is studying the effectiveness of a combination of two medications, decitabine and cedazuridine (called ASTX727), along with venetoclax, for treating specific types of blood canc...

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

NCT ID: NCT06680661

The ABBA CORD clinical trial is designed to test whether adding a medication called abatacept to standard treatments can help prevent a serious complication known as acute graft versus host disease...

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

NCT ID: NCT05038592

This clinical trial is investigating a new treatment for a type of blood cancer called Chronic Myelomonocytic Leukemia (CMML). The treatment combines two medications: tagraxofusp, which targets and...

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

NCT ID: NCT04160052

This clinical trial is studying the combination of two medications, venetoclax and azacitidine, to treat patients with high-risk myelodysplastic syndrome (MDS) that is either recurring or not respo...

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT ID: NCT03670966

This clinical trial is studying a new treatment approach for patients with high-risk acute leukemia or myelodysplastic syndrome, especially those whose disease has come back or is not responding to...

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

NCT ID: NCT06001385

This clinical trial is looking at a new way to help patients with blood cancers, such as leukemia and lymphoma, by using stem cells from unrelated donors who have a different tissue type. The main ...

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

NCT ID: NCT05233618

This clinical trial is studying a medication called tagraxofusp (Tag) for patients who have certain types of blood cancers, specifically myelofibrosis, chronic myelomonocytic leukemia (CMML), and a...

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.

NCT ID: NCT06071624

This clinical trial is testing a new treatment called CD4CAR T-cell therapy for patients with a type of blood cancer known as Chronic Myelomonocytic Leukemia (CMML) that has returned or hasn't resp...

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant

NCT ID: NCT05031897

This clinical trial is studying a new way to prepare patients for a type of cancer treatment called hematopoietic stem cell transplant (HSCT). HSCT can help treat certain blood cancers, but sometim...

Personalized NK Cell Therapy in CBT

NCT ID: NCT02727803

This clinical trial is looking at a new treatment called personalized natural killer (NK) cell therapy for patients with certain types of blood cancers, including leukemia, lymphoma, and myelodyspl...